Modalis Pairs MDL-201 With Muscle-Targeted AAV

Evidence Company-issued announcement · Discovery September 11, 2026 · Importance 4/5 · Direction Uncertain Summary Exegenesis Bio and Modalis Therapeutics entered a research collaboration and license agreement giving Modalis access to EMC181, an engineered muscle-tropic, liver-detargeted adeno-associated virus capsid, for MDL-201. The program combines that…